You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
or call 1-800-FDA-1088.
Please see accompanying full Prescribing Information. For full prescribing information, please visit www.Diclegis.com.
About Nausea and Vomiting of Pregnancy (NVP)Nausea and vomiting of pregnancy (NVP), or morning sickness, affects 70 to 85 percent of pregnant women, with symptoms that range from nausea to severe vomiting and retching. iii,iv For most pregnant women, symptoms generally cease at approximately 16 to 20 weeks. iv However, some women can experience symptoms throughout their pregnancy. iv
About Duchesnay USA Duchesnay USA is a unique healthcare company devoted to safeguarding the health and well-being of expectant mothers and their unborn babies. Its affiliate company, Duchesnay Inc. was founded in 1970 in Canada. The family-owned company realigned its business in 1992 to focus specifically on pregnant women after a family member experienced a very difficult pregnancy. Duchesnay USA was established in Rosemont, Pennsylvania in 2011 to pursue that same mission. Realizing a lack of sufficient information on medications for use in pregnancy, Duchesnay USA strives to ensure that expectant women who require pharmacological treatments have access to proper medical advice and therapies that are safe for them and their unborn babies. Duchesnay USA's mission is to develop pharmacological solutions to reduce the symptoms of nausea and vomiting during pregnancy (NVP). For more information on Duchesnay USA, please visit www.DuchesnayUSA.com.
i Diclegis Product Label ii Department of Health and Human Services, Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register. 2008; 73 (104):30831-68. iii American College of Obstetricians and Gynecologists. Nausea and vomiting of pregnancy. ACOG Practice Bulletin. 2004;52. iv Clark S, Costantine M, Hankins GDV. Review of NVP and HG and early pharmacotherapeutic Intervention. Obstetrics and Gynecology International Volume. 2012. v Duchesnay Inc. – data on fileContact:Laney Cohen(212) 508-9643 email@example.com SOURCE Duchesnay USA